Clinical Trial Update: Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase 3 efficacy and safety study evaluating levomilnacipran ER for major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Levomilnacipran ER (levomilnacipran hydrochloride)

Snippet

Sponsor: Zhejiang Huahai Pharmaceutical Co., Ltd. | Conditions: Major Depressive Disorder (MDD) | Phase 3 | Status: COMPLETED